AngioDynamics, Inc.
NASDAQ:ANGOMedical - Instruments & Supplies
+$0.20 today
- Market cap
- $476.06M
- Beta
- 0.36
- P/E (TTM)
- -15.8
- EPS (TTM)
- -$0.75
Volume 0.32M
Average 0.40M
ANGO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
AngioDynamics, Inc.NASDAQ: ANGO
Cost of Revenue · Q3 FY2026 · quarter ended Feb 2026
Cost of revenue grows in line with its trailing trend
Q3 FY2026 cost of revenue of $36.94M rose 11.5% year over year, behind the +12.9% change in trailing-twelve-month cost of revenue. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at -3.6% a year.
Context
- Cost of revenue amounted to 46.1% of revenue in FY2025, down 3.0 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.5% toward the trailing-twelve-month pace of +12.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 134.79M USD
- Year-over-year change
- -9.7%
- 4-year CAGR
- +0.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-31 | 134.79M | -9.7% |
| FY2024 | 2024-05-31 | 149.22M | -9.3% |
| FY2023 | 2023-05-31 | 164.51M | +9.3% |
| FY2022 | 2022-05-31 | 150.49M | +12.1% |
| FY2021 | 2021-05-31 | 134.22M | — |
Cost of Revenue vs competitors
How ANGO compares with its peers on the latest reported figures
- ANGO's LTM Feb 2026 cost of revenue of $146.03M is the 8th highest of the 9 companies compared; the peer median is $792.29M.
- Its year-over-year change of +12.9% is the highest of 9, against a peer median of +1.1%.
- Cost of revenue amounts to 46.5% of revenue for ANGO, versus a peer median of 46.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $10.72B | -10.1% | -2.9% | 53.0% | |
| LTM Jun 2026 | $6.06B | -11.0% | +7.8% | 28.8% | |
| LTM Jun 2026 | $1.2B | -11.0% | -11.5% | 46.2% | |
| LTM Sep 2026 | $815.11M | +7.2% | +7.2% | 50.6% | |
| LTM Mar 2026 | $769.47M | +2.0% | +10.4% | 46.8% | |
| LTM Mar 2026 | $636.88M | +8.8% | +11.0% | 46.4% | |
| LTM Jun 2026 | $483.98M | +12.8% | +13.9% | 32.2% | |
| LTM Feb 2026 | $146.03M | +12.9% | -3.6% | 46.5% | |
| LTM Mar 2026 | $70.77M | +0.2% | +7.8% | 27.6% | |
| Peer median (excluding ANGO) | $792.29M | +1.1% | +7.8% | 46.3% | |
Competitors are the stored peer set for ANGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 291.01M | 316.22M | 338.75M | 303.91M | 292.5M |
| Cost of Revenue | 134.22M | 150.49M | 164.51M | 149.22M | 134.79M |
| Gross Profit | 156.79M | 165.73M | 174.25M | 154.7M | 157.71M |
| Gross Margin | 53.9% | 52.4% | 51.4% | 50.9% | 53.9% |
| Research & Development | 36.39M | 30.74M | 29.88M | 31.51M | 26.22M |
| Selling, General & Admin | 117.22M | 133.75M | 144.25M | 143.98M | 145.23M |
| Operating Expenses | 192.07M | 194.2M | 225.43M | 347.13M | 197.66M |
| Depreciation & Amortization | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M |
| EBITDA | (9.28M) | 11.13M | 12.19M | (6.13M) | 1.74M |
| EBITDA Margin | -3.2% | 3.5% | 3.6% | -2.0% | 0.6% |
| Operating Income | (35.28M) | (28.47M) | (51.18M) | (192.44M) | (39.95M) |
| Operating Margin | -12.1% | -9.0% | -15.1% | -63.3% | -13.7% |
| Interest Income | 0 | 0 | 0 | 1.61M | 978K |
| Interest Expense | 861K | 688K | 2.7M | 0 | 0 |
| Other Income / Expenses | (769K) | (1.48M) | (3.26M) | 797K | 5.92M |
| Income Before Tax | (36.05M) | (29.95M) | (54.44M) | (191.64M) | (34.03M) |
| Pre-Tax Margin | -12.4% | -9.5% | -16.1% | -63.1% | -11.6% |
| Income Tax Expense | (4.5M) | (3.4M) | (2M) | (7.29M) | (39K) |
| Net Income | (31.55M) | (26.55M) | (52.44M) | (184.35M) | (33.99M) |
| Net Margin | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% |
| EPS (Basic) | (0.82) | (0.68) | (1.33) | (4.59) | (0.83) |
| EPS (Diluted) | (0.82) | (0.68) | (1.33) | (4.59) | (0.83) |
| Weighted Avg Shares | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M |
| Weighted Avg Shares (Diluted) | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M |
AngioDynamics, Inc.
NASDAQ:ANGO
Intrinsic Alpha fair value
Locked
Current Price
$11.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.